N-3 Fatty Acids for the Prevention of Atrial Fibrillation After Coronary Artery Bypass Surgery A Randomized, Controlled Trial

Size: px
Start display at page:

Download "N-3 Fatty Acids for the Prevention of Atrial Fibrillation After Coronary Artery Bypass Surgery A Randomized, Controlled Trial"

Transcription

1 Journal of the American College of Cardiology Vol. 45, No. 10, by the American College of Cardiology Foundation ISSN /05/$30.00 Published by Elsevier Inc. doi: /j.jacc N-3 Fatty Acids for the Prevention of Atrial Fibrillation After Coronary Artery Bypass Surgery A Randomized, Controlled Trial Leonardo Calò, MD, FESC, Leopoldo Bianconi, MD, Furio Colivicchi, MD, FESC, Filippo Lamberti, MD, Maria Luisa Loricchio, MD, Ermenegildo de Ruvo, MD, Antonella Meo, MD, Claudio Pandozi, MD, FESC, Mario Staibano, MD, Massimo Santini, MD, FESC, FACC Rome, Italy OBJECTIVES BACKGROUND The aim of this study was to assess the efficacy of preoperative and postoperative treatment with n-3 polyunsaturated fatty acids (PUFAs) in preventing the occurrence of atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG). Postoperative AF is a common complication of CABG. There is growing clinical evidence that PUFAs have cardiac antiarrhythmic effects. METHODS A total of 160 patients were prospectively randomized to a control group (81 patients, 13 female, years) or PUFAs 2 g/day (79 patients, 11 female, years) for at least 5 days before elective CABG and until the day of discharge from the hospital. The primary end point was the development of AF in the postoperative period. The secondary end point was the hospital length of stay after surgery. All end points were independently adjudicated by two cardiologists blinded to treatment assignment. RESULTS CONCLUSIONS The clinical and surgical characteristics of the patients in the two groups were similar. Postoperative AF developed in 27 patients of the control group (33.3%) and in 12 patients of the PUFA group (15.2%) (p 0.013). There was no significant difference in the incidence of nonfatal postoperative complications, and postoperative mortality was similar in the PUFA-treated patients (1.3%) versus controls (2.5%). After CABG, the PUFA patients were hospitalized for significantly fewer days than controls ( days vs days, p 0.017). This study first demonstrates that PUFA administration during hospitalization in patients undergoing CABG substantially reduced the incidence of postoperative AF (54.4%) and was associated with a shorter hospital stay. (J Am Coll Cardiol 2005;45:1723 8) 2005 by the American College of Cardiology Foundation Atrial fibrillation (AF) is the most common complication associated with coronary artery bypass graft surgery (CABG) (1). In addition, postoperative AF imparts an increased risk for other major complications after cardiac surgery, while also prolonging hospital length of stay, and increasing costs (1). Owing to such relevant clinical and economic implications, several studies have been undertaken in order to define effective pharmacological and nonpharmacological interventions for the prevention of this troublesome arrhythmia (2 4). Recent experimental and clinical studies have shown that n-3 polyunsaturated fatty acids (PUFAs) may be effective in preventing cardiac arrhythmias and sudden death (5 25). In particular, PUFAs have shown significant antiarrhythmic effects on the atrial muscle in rat experimental models (24). Furthermore, the human consumption of fish inducing high plasma PUFA concentration has been associated with a lower incidence of AF in a 12-year follow-up study (25). The aim of this study was to assess the efficacy and safety of preoperative and postoperative treatment with n-3 PUFA in preventing the occurrence of AF after CABG. From the Department of Cardiac Diseases, San Filippo Neri Hospital, Rome, Italy. Manuscript received January 20, 2005; revised manuscript received February 18, 2005, accepted February 22, METHODS Patients. The study cohort consisted of 160 patients (136 men and 24 women; mean age, years) undergoing CABG. These patients were recruited from consecutive subjects referred to our institution from February 2003 to August 2004 for elective cardiac surgery. To be included in the study, patients needed to be older than 18 years of age, in normal sinus rhythm, and in stable hemodynamic conditions before surgery. Patients were excluded in the following cases: need for concomitant valvular surgery; prior history of any kind of supraventricular arrhythmias; current use of antiarrhythmic medications other than beta-receptor antagonists, calcium-channel antagonists, or digitalis. All enrolled patients provided written informed consent to take part in the investigation. Study design. The study was planned as an open-label, prospective, randomized, controlled trial with parallel groups. The main goal of the study was to assess the effects of PUFAs in the prevention of the occurrence of AF after coronary surgery. The study protocol was approved by the ethics committee of our institution. Also, as currently used at our institution for investigator-initiated research that is not supported by any industrial grant, the ethics committee also served as the data safety committee. Eligible patients were assigned to one of the two study

2 1724 Calò et al. JACC Vol. 45, No. 10, 2005 N-3 Fatty Acids and Postoperative AF May 17, 2005: Abbreviations and Acronyms AF atrial fibrillation CABG coronary artery bypass graft surgery CI confidence interval DHA docosahexaenoic acid EPA eicosapentaenoic acid OR odds ratio PUFA n-3 polyunsaturated fatty acid arms according to a computer-generated randomization list: 1) control group (usual care); and 2) usual care plus PUFAs. Therapy with PUFAs, at the dosage of two capsules/day, was started immediately after randomization and continued for at least five days before surgery. In the absence of evidence for preferred doses of treatments, we decided on the daily doses of n-3 PUFAs as two gelatin capsules containing 850 to 882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters in the average ratio of EPA/DHA 1:2 (8,9). This pharmaceutical product is commercially available in Italy (Società Prodotti Antibiotici, Milan, Italy) and has already been used in other trials (8,9). The administration of PUFAs in the immediate postoperative period (24 to 36 h) was done, if needed, through a nasogastric tube. Treatment with PUFAs continued until hospital discharge. Compliance was monitored by pill count and was 98%. The study was not funded by any pharmaceutical company (except for the provision of PUFAs without costs). Midline sternotomy procedures with standard surgical techniques for cardiopulmonary bypass in CABG were used. Nineteen patients underwent off-pump CABG. Myocardial protection was afforded with cold potassium cardioplegia. After surgery patients were admitted to the intensive care unit and were subsequently transferred to a monitored intermediate care unit. In these two settings, continuous rhythm monitoring was performed for the first four to five postoperative days. The electrocardiographic data were stored for 24 h and reviewed on a daily basis by the cardiac surgery team. The printouts of all abnormal rhythms were also reviewed for any episodes of arrhythmia by the attending cardiologist. All printouts were included in clinical records. After discharge from the monitored intermediate care unit to the cardiovascular ward, patients had an electrocardiogram daily until hospital discharge. Additionally, an electrocardiogram was also recorded in case of symptoms or when an arrhythmia was suspected on clinical grounds; AF episodes were always treated under the direction of the attending cardiologist. After discharge all patients were asked to report to the outpatient department of our institution in case of any relevant symptom. Additionally, all patients had a follow-up visit four weeks after discharge, including physical examination and a 12-lead electrocardiogram. Study end points. The primary end point of the study was the development of postoperative AF as detected by electrocardiography during the hospitalization period. Postoperative AF was defined as any electrocardiographically confirmed episode of AF for 5 min in duration or requiring intervention for angina or hemodynamic compromise. After an episode of AF or at hospital discharge, formal study participation ended, and the patient was withdrawn from any further analysis. The secondary end point was the hospital length of stay after surgery. All end points were independently adjudicated after discharge by two cardiologists, blinded to treatment assignment, on the basis of clinical records and electrocardiographic tracings. Statistical analysis. The primary analysis of all outcomes was by intention-to-treat. The occurrence of postoperative AF in the two treatment groups was tested with the odds ratio (OR) of the two-binomial proportion analysis. The cumulative risk of occurrence of AF within each group was estimated by means of the Kaplan-Meier method. The survival curves of the two different treatment groups were then formally compared by use of the log-rank test. Mean ( SD) were calculated for continuous variables, and frequencies were measured for categorical variables. Differences between groups were analyzed by an unpaired Student t test for continuous variables, while, in case of categorical variables, group differences were examined by chi-square or Fisher exact tests as appropriate. In particular, the Fisher exact tests was applied in case of an expected frequency of 5. A value of p 0.05 was considered significant. Sample size calculation was based on an expected 35% occurrence of postoperative AF in the control group and on an expected 20% occurrence of AF in the PUFA arm. Consequently, with a significance level of 0.05 and a test power of 0.80, the resulting sample size was 138 patients in each treatment group. A stepwise logistic regression analysis was performed to select the predictors of AF after surgery. The model was built using variables that demonstrated a p value 0.10 in univariate analysis. The significance within the model was evaluated with the Wald statistical test. All tests were two-tailed and performed by SPSS 11.5 statistic software (Chicago, Illinois). According to the study protocol, an interim analysis of safety and efficacy was planned every six months during the study. RESULTS Enrollment was started in February 2003, and the third formal interim analysis was performed on August 30, By that time, 160 patients had been enrolled, and complete data were available for all patients. The interim

3 JACC Vol. 45, No. 10, 2005 May 17, 2005: Calò et al. N-3 Fatty Acids and Postoperative AF 1725 analysis showed a significant effect in favor of the PUFA group compared with controls (p 0.013). Consequently, in accordance with the ethics committee of our institution, a decision was made to terminate enrollment. The study results were then reported as of September 12, Of the 160 patients enrolled in the study, 81 were assigned by randomization to the control group and 79 to the PUFA group. The two groups were similar with regard to all clinical and surgical characteristics, as shown in Table 1. The overall incidence of AF in the whole study sample was 24.4% (39 of 160 patients). Postoperative AF occurred in 15.2% (12 of 79) of the patients in the PUFA group compared with 33.3% (27 of 81) of those in the control group (OR 0.35; 95% confidence interval [CI] 0.16 to 0.76; p 0.013). The consequent number of patients needed to treat was 5.51 (95% CI 3.43 to 20.40). The Kaplan-Meier actuarial estimates of occurrence of postoperative AF in the study group are shown in Figure 1. Atrial fibrillation occurred a mean of days after surgery in patients assigned to PUFAs and days after surgery in controls (p 0.645); AF was diagnosed during continuous electocardiographic monitoring in the intensive or intermediate care units in 11 of 12 (91.6%) patients in the PUFA group and in 25 of 27 (92.5%) patients in the control group (p by chi-square). The remaining cases of AF (one in the PUFA group and two in the control group) were detected by electrocardiography after the occurrence of symptoms. The mean duration of AF was of h in patients assigned to PUFA and h in controls (p 0.125). Symptoms attributable to AF were reported by 10 of 12 patients (83.3%) in the PUFA group and by 24 of 27 (88.8%) controls (p by chi-square); AF was initially treated by amiodarone in 9 of 12 patients assigned to PUFA and in 22 of 27 controls (p by chi-square). Spontaneous conversion to sinus rhythm without any intervention occurred in two patients receiving PUFAs and in three controls (p by Fisher exact test). Electrical cardioversion was performed on one patient in the PUFA group and in two controls (p by Fisher exact test). Two of 12 (16.6%) patients in the PUFA group had more than one episode of AF during hospitalization (two episodes and three episodes, respectively), while 5 of 27 (18.5%) patients in the control group had more than one episode of AF (three patients had two episodes and two patients had three episodes) (p by Fisher exact test). Four patients (two from the PUFA group and two controls) presented to the outpatient department owing to acute symptoms (dyspnea, fatigue, chest discomfort) after discharge and before the planned follow-up visit. In all of these cases, sinus rhythm was present. Patients had a follow-up visit in the outpatient department 28 8 days after surgery, and sinus rhythm was present in each patient. In the multivariate analysis, two variables were noted to be significant independent predictors of postoperative AF: age (OR 1.08; 95% CI 1.01 to 1.15; p 0.022) and the use of PUFAs (OR 0.32; 95% CI 0.10 to 0.98; p 0.013). Table 1. Patients Clinical and Surgical Data Controls (n 81) PUFAs (n 79) p Value* Age, yrs Male gender 68 (84%) 68 (86%) 0.88 Systemic hypertension 66 (81.5%) 62 (78.5%) 0.78 Diabetes mellitus 26 (32.1%) 26 (32.9%) 1.0 COP disease 13 (16%) 13 (16.4%) 0.94 Chronic renal failure 7 (8.6%) 8 (10.1%) 0.74 NYHA functional class Previous myocardial infarction 43 (53.1%) 41 (51.9%) 1.0 Perioperative medication Beta-blockers 46 (56.8%) 46 (58.2%) 0.98 Calcium channel blockers 25 (30.9%) 22 (27.8%) 0.67 Nitrates 61 (75.3%) 60 (74.1%) 0.92 Diuretics 26 (32.1%) 24 (30.4%) 0.81 ACE inhibitors 48 (59.3%) 46 (58.2%) 0.89 Angiotensin receptor blockers 15 (18.5%) 18 (22.8%) 0.50 Statins 44 (54.3%) 47 (59.4%) 0.50 Acitelsalicilic acid 44 (54.3%) 47 (59.4%) 0.50 Ejection fraction, % Left atrial AP dimension, mm Cardiopulmonary bypass time, min Aorta cross-clamp time, min Sapheneous vein grafts, no./patient Internal thoracic artery grafts, no./patient Off pump CABG 10 (12.3%) 9 (11.4%) 0.95 *All comparisons for categorical variables were performed by chi-square analysis. AP anteroposterior; ACE angiotensin-converting enzyme; CABG coronary artery bypass surgery; COP chronic obstructive pulmonary; NYHA New York Heart Association; PUFAs polyunsaturated fatty acids.

4 1726 Calò et al. JACC Vol. 45, No. 10, 2005 N-3 Fatty Acids and Postoperative AF May 17, 2005: Figure 1. The Kaplan-Meier actuarial estimates of occurrence of postoperative atrial fibrillation in the study group. PUFA n-3 polyunsaturated fatty acids. Influence of beta-blocker therapy. The use of betablockers did not influence the prevalence of AF in either study group. Of 79 patients on PUFAs, 46 (56.8%) were on beta-blockers. Of these, seven (15.2%) developed AF, whereas five (15.1%) of the patients not taking betablockers had AF. In the control group, the prevalence of AF was 34.8% (16 of 46 patients) among the patients on beta-blockers and 31.4% (11 of 35 patients) among those not receiving beta-blockers. In-hospital morbidity and mortality. One patient in the PUFA group developed allergic skin rash on the first day of drug administration, and PUFAs were discontinued. Nonfatal postoperative complications occurred in seven (8.6%) patients of the control group (two acute renal failure, one pneumonia, two pneumotorax, one pulmonary edema, one gastrointestinal bleeding) and in five (6.3%) patients of the PUFA group (one acute renal failure, one implantation of permanent pacemaker, one pneumotorax, one adult respiratory distress syndrome, one redo for pericardial bleeding) (p 0.8 by Fisher exact test). There were two deaths in the control group (2.5%) and one death in the PUFA group (1.3%) (p 1.0 by Fisher exact test). Length of hospital stay. Patients assigned to PUFAs had a shorter length of hospital stay as compared with controls ( days, 95% CI for mean 6.8 to 7.7 vs days, 95% CI for mean 7.6 to 8.7, p 0.017). When considering the overall population, patients with AF had a longer length of hospital stay than those without AF ( days, 95% CI for mean 8.4 to 10.3 vs days, 95% CI for mean 6.8 to 7.5, p ). In the PUFA group, the mean length of stay was days (95% CI for mean 7.5 to 11.5) for patients with AF and days (95% CI for mean 6.4 to 7.2) for those without AF (p 0.01). In the control group, patients with AF also had a longer hospital stay as compared with those without AF ( days, 95% CI for mean 8.1 to 10.4 vs days, 95% CI for mean 7.0 to 8.2, p 0.01). DISCUSSION Main findings. In this trial, the use of PUFAs during hospitalization in patients undergoing CABG significantly reduced the incidence of postoperative AF (18.1% absolute risk reduction, 54.4% relative risk reduction) and was associated with a shorter hospital stay. Except for a single case of allergic response, no significant adverse reactions were observed. Previous studies. The issue of prevention of postoperative AF in cardiac surgery was addressed by a number of studies. Several agents, including digitalis, calcium antagonists, procainamide, quinidine, and propafenone did not show any beneficial effect (1,26 29). A meta-analysis, which included 42 trials conducted before 2001, compared several agents (beta-blockers, sotalol, and amiodarone) with placebo (2). Beta-blockers (27 trials, 3,840 patients) were found to reduce the incidence of AF from 33% to 19%, while sotalol (8 trials, 1,294 patients) reduced the occurrence of the arrhythmia from 37% to 17%. In four comparative trials

5 JACC Vol. 45, No. 10, 2005 May 17, 2005: Calò et al. N-3 Fatty Acids and Postoperative AF 1727 (900 patients), sotalol scored better than conventional betablockers (12% incidence of AF vs. 22%). However, all trials employing beta-blockers or sotalol excluded patients with bradycardia and obstructive lung disease. Moreover, most studies excluded patients with depressed left ventricular function or heart failure. Amiodarone was evaluated in nine trials, including 1,384 patients, and reduced the occurrence of AF from 37% to 22.5%. Also, a recent trial compared amiodarone plus metoprolol, metoprolol alone, and sotalol with placebo (29). Only the combination therapy and sotalol reduced the relative risk of postoperative AF, respectively, by 45% and 41%. In this study, the incidence of AF in the placebo group was of 33%, which is similar to the mean incidence of AF reported in the literature. In our study, PUFAs determined a reduction of the relative risk of postoperative AF of 54.4%, thereby favorably comparing with the 43% reduction obtained by beta-blockers, the 54% reduction observed with sotalol, and the 39% reduction associated with amiodarone use. In addition, differently from beta-blockers and sotalol, which can be associated with cases of significant bradycardia and persistent hypotension (29), PUFAs showed a particularly low incidence of adverse effects, and could be used in all patients, including those with respiratory insufficiency or heart failure. The antiarrhythmic effect of PUFAs. Back in 1985, a study first reported that polyunsaturated alpha-linoleic acid lowered the arrhythmia threshold of the isolated rabbit heart (16). Several reports followed such initial findings and demonstrated that PUFAs may exert a protective effect against fatal ventricular arrhythmias in animal models after experimental coronary ligation (18,19). The electrophysiological basis of such effect has been clarified in other studies, showing at least three possible modes of action for the PUFAs on the myocyte (6,7,17): a slight hyperpolarization of the resting membrane potential, an increase of the current necessary to elicit an action potential, and an increase of the phase 4 refractory period. These effects were found to be related to an inhibition of the sodium current I Na (12), of the calcium current I CaL (15), and, possibly, of the potassium currents I K and I to (6). These effects account for an increased electrical stability that may result in a significant protection against fibrillation, which has been actually demonstrated in vitro (17). Epidemiological surveys suggest that fish oil consumption may reduce the risk of fatal ventricular arrhythmias, consistently supporting an antiarrhythmic effect of PUFAs (9,10,21 25). The main hypothesis of our study was that the antiarrhythmic properties of PUFAs could also extend to the atrial myocardium, thereby protecting against the occurrence of AF. Actually, even if a previous study showed that PUFAs may reduce the asynchronous contractile activity of atrial myocytes (24), to date, the effects of PUFAs on supraventricular arrhythmias have not been fully investigated. In fact, our findings represent the first direct evidence that PUFA supplementation may, indeed, be effective in preventing AF. Furthermore, our findings are in keeping with a recent study in which the consumption of tuna, and other broiled or baked fish, was associated with a 30% lower incidence of AF in a 12-year follow-up (25). Interestingly, only the consumption of fish inducing higher concentrations of long chain n-3 fatty acids was associated with an antiarrhythmic effect, while the intake of fried fish or fish sandwiches did not induce higher plasma levels of PUFAs and did not show any protective effect against AF. The anti-inflammatory hypothesis. A possible role of inflammation in the pathophysiology of postoperative AF has been repeatedly suggested (30,31), and the antiinflammatory activity of PUFAs is now well-documented (32 35). There are several clinical studies reporting that PUFAs have beneficial effects in acute and chronic inflammatory diseases (32 34). Furthermore, it has been observed that EPA can act as a competitive inhibitor of arachidonic acid conversion to prostaglandin E 2 and leukotriene B 4, while a decreased synthesis of both of these eicosanoids has been observed after inclusion of fish oil in the diet (32,33). The inclusion of DHA in the diet may also result in decreased synthesis of leukotriene B 4 (32,33). As to the proinflammatory cytokines, it has been shown that dietary supplementation with encapsulated fish oil may result in a decreased monocyte synthesis of tumor necrosis factor-alpha and interleukin 1 in humans (35). Consequently, we can hypothesize that an anti-inflammatory action of PUFAs could play a role in the prevention of AF after cardiothoracic surgery. Study limitations. The present study was not formally blinded; we acknowledge this as a limitation. However, this methodological limit should not have influenced the main results of the trial. In fact, two independent cardiologists, who were blinded to treatment allocation, formally adjudicated the primary end point of the study and computed the hospital length of stay on the basis of clinical records and electrocardiographic tracings after discharge. This approach somehow resembles that used in other trials, which employed a blinded end point committee (36). Patients undergoing valvular surgery and patients with previous AF were excluded. Both valvular surgery and history of AF are factors that increase the risk of postoperative AF (1). Consequently, patients with these conditions were preliminarily excluded in order to avoid any possible confounding factor. The results of the present study are, therefore, applicable only to patients with no history of AF undergoing isolated CABG. The patients in the PUFA group were hospitalized for significantly fewer days than those in the control group. Consequently, patients assigned to PUFA may possibly have had asymptomatic episodes of AF after discharge that were not identified. We also acknowledge this point as a potential limitation of the study. Conclusions. n-3 Polyunsaturated fatty acid supplementations in patients undergoing isolated CABG significantly reduces the occurrence of postoperative AF, with an effect

6 1728 Calò et al. JACC Vol. 45, No. 10, 2005 N-3 Fatty Acids and Postoperative AF May 17, 2005: that is similar to that obtained with beta-blockers, sotalol, and amiodarone. In addition, PUFA supplementation is safe and can be administered to all patients undergoing CABG without the exclusion of any patient. This is the first direct evidence of an atrial antiarrhythmic effect of PUFAs and may pave the way to other studies aimed at defining any possible atrial antifibrillatory effect of PUFAs in other clinical conditions. Reprint requests and correspondence: Dr. Leonardo Caló, Department of Cardiology, San Filippo Neri Hospital, Via della Pedica, 348, Grottaferrata, Rome, Italy. leonardo.calo@tin.it. REFERENCES 1. Ommen SR, Odell KA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997;336: Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery. A meta-analysis. Circulation 2002;106: Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized trials. Am J Med 2004;117: Zimmer J, Pezzullo J, Choucair W, et al. Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery. Am J Cardiol 2003;91: Jouven X, Charles M-A, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001;104: Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J 2001;3 Suppl D:D Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids: recent studies. Circulation 1996;94: Marchioli R, Barzi F, Bomba E, et al., on behalf of the GISSI- Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: timecourse analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105: GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354: Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and risk of sudden death. N Engl J Med 2002;346: Billman GE, Kang JX, Leaf A. Prevention of ischemia-induced ventricular arrhythmias by dietary pure n-3 polyunsaturated fatty acids in dogs. Circulation 1999;99: Xiao Y-F, Wright SN, Wang GK, Morgan JP, Leaf A. N-3 fatty acids suppress voltage-gated Na currents in HEK293t cells transfected with the -subunit of the human cardiac Na channel. Proc Natl Acad SciUSA1998;95: Xiao Y-F, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca 2 currents by polyunsaturated fatty acids in adult and neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 1997;94: Murnaghan MF. Effects of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit. Br J Pharmacol 1981;73: Kang JX, Xiao Y-F, Leaf A. Free long-chain polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 1995;92: McLennan PL. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rat. Am J Clin Nutr 1993;57: McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J 1992;123: Kang JX, Leaf A. Prevention and termination of arrhythmias induced by lysophosphatidyl choline and acylcarnitine in neonatal rat cardiac myocytes by free omega-3 polyunsaturated fatty acids. Eur J Pharmacol 1996;297: Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and risk of primary cardiac arrest. JAMA 1995;274: Albert CM, Hennekens CH, O Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279: Lemaitre RN, King I, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. Plasma phospolipid n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal MI in older adults-chs. Am J Clin Nutr 2003;77: Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed-chs. Circulation 2003;107: McLennan PL. Myocardial membrane fatty acids and antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001;36:111S 4S. 24. Jahangiri A, Leifert WR, Patten GS, McMurchie EJ. Termination of asynchronous contractile activity in rat atrial myocytes by n-3 poliunsaturated fatty acids. Mol Cell Biochem 2000;206: Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110: Laub GW, Janeira L, Muralidharan S, et al. Prophylactic procainamide for the prevention of atrial fibrillation after coronary artery bypass grafting: a prospective double-blind, randomized, placebocontrolled pilot study. Crit Care Med 1993;21: McCarty RJ, Jahnke EJ, Walker WJ. Ineffectiveness of quinidine in preventing atrial fibrillation following mitral valvotomy. Circulation 1966;34: Kowey PR, Yannicelli D, Amsterdam E, for the COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004; 94: Auer J, Weber T, Berent R, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the Pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004;147: Gaudino M, Andreotti F, Zamparelli R, et al. The 174G/C interleukin-6 polymorphism influences post-operative interleukin-6 levels and post-operative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003;108 Suppl II:II Bruins P, Velthuis H, Yazdanbakhsh AP. Activation of the complement system during and after cardiopulmonary bypass surgery. Circulation 1997;96: Mori TA, Chem CP, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6: Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001;36: Harbige LS. Fatty acids, the immune response, and auto-immunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 2003;38: Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320: Herlitza J, Holmb J, Petersonc M, Karlsona B, Evandera MH, Erhardtb L, for the LoWASA Study Group. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA study. Eur Heart J 2004;25:232 9.

n 3 FATTY ACIDS AND SUDDEN DEATH BLOOD LEVELS OF LONG-CHAIN n 3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH

n 3 FATTY ACIDS AND SUDDEN DEATH BLOOD LEVELS OF LONG-CHAIN n 3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH n 3 FATTY ACIDS AND SUDDEN DEATH BLOOD LEVELS OF LONG-CHAIN n 3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH CHRISTINE M. ALBERT, M.D., M.P.H., HANNIA CAMPOS, PH.D., MEIR J. STAMPFER, M.D., DR.P.H., PAUL M.

More information

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation Roberto Marchioli, MD, on behalf of the OPERA Investigators American Heart Association, Los Angeles November 5, 2012 Published online

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

Randomized, double blind, placebo-controlled, for the maintenance of normal sinus rhythm in. FORωARD

Randomized, double blind, placebo-controlled, for the maintenance of normal sinus rhythm in. FORωARD Randomized, double blind, placebo-controlled, independent study to test the efficacy of n-3 3PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. FORωARD (Fish

More information

Effect of Dietary Fish Oil on Atrial Fibrillation After Cardiac Surgery

Effect of Dietary Fish Oil on Atrial Fibrillation After Cardiac Surgery Effect of Dietary Fish Oil on Atrial Fibrillation After Cardiac Surgery Aaron L. Farquharson, MNursSc a, Robert G. Metcalf, PhD b,e, *, Prashanthan Sanders, MBBS, PhD b,f, Robert Stuklis, MBBS g, James

More information

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac

More information

Polypharmacy - arrhythmic risks in patients with heart failure

Polypharmacy - arrhythmic risks in patients with heart failure Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012

More information

Controversies with regard to 'upstream therapy of atrial fibrillation

Controversies with regard to 'upstream therapy of atrial fibrillation Controversies with regard to 'upstream therapy of atrial fibrillation Barbara Casadei Department of Cardiovascular Medicine John Radcliffe Hospital University of Oxford No conflict of interest to declare

More information

The pill-in-the-pocket strategy for paroxysmal atrial fibrillation

The pill-in-the-pocket strategy for paroxysmal atrial fibrillation The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,

More information

Dietary intake of long-chain n 3 polyunsaturated fatty acids and the risk of primary cardiac arrest 1 3

Dietary intake of long-chain n 3 polyunsaturated fatty acids and the risk of primary cardiac arrest 1 3 Dietary intake of long-chain n 3 polyunsaturated fatty acids and the risk of primary cardiac arrest 1 3 David S Siscovick, TE Raghunathan, Irena King, Sheila Weinmann, Viktor E Bovbjerg, Lawrence Kushi,

More information

Journal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.

Journal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary

More information

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary- The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Fish Oil Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable Defibrillators

Fish Oil Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable Defibrillators ORIGINAL CONTRIBUTION Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable Defibrillators A Randomized Controlled Trial Merritt H. Raitt, MD William

More information

Journal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.

Journal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32. Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

Role of Omega-3 Fatty Acids in the Prevention of Atrial Fibrillation

Role of Omega-3 Fatty Acids in the Prevention of Atrial Fibrillation TreaTmenT UpdaTe Role of Omega-3 Fatty Acids in the Prevention of Atrial Fibrillation Subrata Kar, DO Division of Cardiovascular Medicine, University of Missouri-Columbia School of Medicine, Columbia,

More information

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active

More information

Should I use statins?

Should I use statins? I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of

More information

Amiodarone Prescribing and Monitoring: Back to the Future

Amiodarone Prescribing and Monitoring: Back to the Future Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran

More information

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, G. PAPANIKOLAOU GH, THESSALONIKI The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH

More information

Diagnostic, Technical and Medical

Diagnostic, Technical and Medical Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX Background

More information

Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA

Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA Structure of Omega-3 and Omega-6 Fatty Acids Omega-6 fatty acids CH 3 Omega-3 fatty

More information

» A new drug s trial

» A new drug s trial » A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause

More information

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan

More information

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Atrial Fibrillation and Heart Failure: A Cause or a Consequence Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November

More information

Atrial fibrillation (AF) is the most common cardiac

Atrial fibrillation (AF) is the most common cardiac Fish Intake and Risk of Incident Atrial Fibrillation Dariush Mozaffarian, MD, MPH; Bruce M. Psaty, MD, PhD; Eric B. Rimm, ScD; Rozenn N. Lemaitre, PhD, MPH; Gregory L. Burke, MD, MS; Mary F. Lyles, MD;

More information

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL

More information

Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation

Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation Journal of the American College of Cardiology Vol. 61, No. 4, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.021

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Samer Nasr, M.D. Mount Lebanon Hospital.

Samer Nasr, M.D. Mount Lebanon Hospital. Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not

More information

The benefit of treatment with -blockers in heart failure is

The benefit of treatment with -blockers in heart failure is Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,

More information

Omega-3 Fatty Acid: A Role in the Management of Cardiac Arrhythmias?

Omega-3 Fatty Acid: A Role in the Management of Cardiac Arrhythmias? THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 14, Number 8, 2008, pp. 965 974 Mary Ann Liebert, Inc. DOI: 10.1089/acm.2007.0765 Omega-3 Fatty Acid: A Role in the Management of Cardiac Arrhythmias?

More information

Omega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM

Omega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Omega-3 Fatty Acids Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Chattanooga @a_l_bailey Disclosures None Objectives Describe omega-3 fatty acids Review the historic

More information

Shervin Ziabakhsh Tabary., Asian Journal of Pharmaceutical Technology & Innovation, 02 (05); 2014; 01-08

Shervin Ziabakhsh Tabary., Asian Journal of Pharmaceutical Technology & Innovation, 02 (05); 2014; 01-08 Shervin Ziabakhsh Tabary., Asian Journal of Pharmaceutical Technology & Innovation, 02 (05); 2014; 01-08 Asian Journal of Pharmaceutical Technology & Innovation ISSN: 2347-8810 Received on: 18-02-2014

More information

n 3 Fatty Acids and Cardiovascular Events after Myocardial Infarction

n 3 Fatty Acids and Cardiovascular Events after Myocardial Infarction T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article n 3 Fatty Acids and Cardiovascular Events after Myocardial Infarction Daan Kromhout, M.P.H., Ph.D., Erik J. Giltay, M.D., Ph.D., and

More information

Future directions for nutritional and therapeutic research in omega-3 3 lipids

Future directions for nutritional and therapeutic research in omega-3 3 lipids Future directions for nutritional and therapeutic research in omega-3 3 lipids Philip Calder Professor of Nutritional Immunology University of Southampton Aim To review dietary sources and intakes of long

More information

Atrial fibrillation in the ICU

Atrial fibrillation in the ICU Atrial fibrillation in the ICU Atrial fibrillation Preexisting or incident (new onset) among nearly one in three critically ill patients Formation of arrhythogenic substrate usually fibrosis (CHF, hypertension,

More information

AF Today: W. For the majority of patients with atrial. are the Options? Chris Case

AF Today: W. For the majority of patients with atrial. are the Options? Chris Case AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial

More information

Omega-3 Fatty Acid Effect in Cardiovascular Disease Risk Factors

Omega-3 Fatty Acid Effect in Cardiovascular Disease Risk Factors Volume 1, Issue no. 1, DOI 10.18502/ajne.v1i1.1220 Production and Hosting by Knowledge E Research Article Omega-3 Fatty Acid Effect in Cardiovascular Disease Risk Factors Alketbi Fatima Mohammed, Bolaji

More information

Supplementary Online Content. Mozaffarian D, Marchioli R, Macchia A, et al; for the OPERA Investigators. Fish oil and

Supplementary Online Content. Mozaffarian D, Marchioli R, Macchia A, et al; for the OPERA Investigators. Fish oil and Supplementary Online Content Mozaffarian D, Marchioli R, Macchia A, et al; for the OPERA Investigators. Fish oil and postoperative atrial fibrillation: The Omega-3 Fatty Acids for Prevention of POst-operative

More information

AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!

AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research

More information

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias

More information

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125 145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency

More information

The Effect of Fish Oil On Cardiovascular Mortality Resident Pharmacotherapy Rounds

The Effect of Fish Oil On Cardiovascular Mortality Resident Pharmacotherapy Rounds The Effect of Fish Oil On Cardiovascular Mortality Resident Pharmacotherapy Rounds Kerry-Ann Fuller, PharmD PGY1 Resident UT/HEB Community Pharmacy Residency Preceptor: James Weems, RPh Residency Director:

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Supplementary Online Content

Supplementary Online Content 1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing

More information

Online Appendix (JACC )

Online Appendix (JACC ) Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis

More information

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology

More information

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,

More information

Risk Factors for Ischemic Stroke: Electrocardiographic Findings

Risk Factors for Ischemic Stroke: Electrocardiographic Findings Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Progression From Paroxysmal to Persistent Atrial Fibrillation

Progression From Paroxysmal to Persistent Atrial Fibrillation Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.11.040

More information

Dronedarone for the treatment of non-permanent atrial fibrillation

Dronedarone for the treatment of non-permanent atrial fibrillation Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology

More information

The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting

The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic

More information

AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT

AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

Management of new-onset AF: Initial rate control treatment

Management of new-onset AF: Initial rate control treatment Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to

More information

Postoperative Atrial Fibrillation: Prophylaxis and Treatment

Postoperative Atrial Fibrillation: Prophylaxis and Treatment Postoperative Atrial Fibrillation: Prophylaxis and Treatment Ralph J. Damiano Jr. John Shoenberg Professor of Surgery Chief, Cardiac Surgery Vice Chairman, Department of Surgery Barnes Jewish Hospital

More information

The Incidence and Predictors of Postoperative Atrial Fibrillation After Noncardiothoracic Surgery

The Incidence and Predictors of Postoperative Atrial Fibrillation After Noncardiothoracic Surgery ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.3.100 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology The Incidence and Predictors of Postoperative Atrial Fibrillation

More information

The objective of this study was to determine the longterm

The objective of this study was to determine the longterm The Natural History of Lone Atrial Flutter Brief Communication Sean C. Halligan, MD; Bernard J. Gersh, MBChB, DPhil; Robert D. Brown Jr., MD; A. Gabriela Rosales, MS; Thomas M. Munger, MD; Win-Kuang Shen,

More information

Managing Hypertension in the Perioperative Arena

Managing Hypertension in the Perioperative Arena Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,

More information

Transplantation. Omega-3 Fatty Acids in Cardiac Biopsies From Heart Transplantation Patients

Transplantation. Omega-3 Fatty Acids in Cardiac Biopsies From Heart Transplantation Patients Transplantation Omega-3 Fatty Acids in Cardiac Biopsies From Heart Transplantation Patients Correlation With Erythrocytes and Response to Supplementation William S. Harris, PhD; Scott A. Sands, PhD; Sheryl

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

Cost-effectiveness of minimally invasive coronary artery bypass surgery Arom K V, Emery R W, Flavin T F, Petersen R J

Cost-effectiveness of minimally invasive coronary artery bypass surgery Arom K V, Emery R W, Flavin T F, Petersen R J Cost-effectiveness of minimally invasive coronary artery bypass surgery Arom K V, Emery R W, Flavin T F, Petersen R J Record Status This is a critical abstract of an economic evaluation that meets the

More information

Atrial Fibrillation Predicts Worse Long Time Prognosis after CABG A 6-Year Survival Analysis

Atrial Fibrillation Predicts Worse Long Time Prognosis after CABG A 6-Year Survival Analysis Open Journal of Thoracic Surgery, 2012, 2, 18-22 http://dx.doi.org/10.4236/ojts.2012.22006 Published Online June 2012 (http://www.scirp.org/journal/ojts) Atrial Fibrillation Predicts Worse Long Time Prognosis

More information

Intraoperative and Postoperative Arrhythmias: Diagnosis and Treatment

Intraoperative and Postoperative Arrhythmias: Diagnosis and Treatment Intraoperative and Postoperative Arrhythmias: Diagnosis and Treatment Karen L. Booth, MD, Lucile Packard Children s Hospital Arrhythmias are common after congenital heart surgery [1]. Postoperative electrolyte

More information

Review guidance for patients on long-term amiodarone treatment

Review guidance for patients on long-term amiodarone treatment Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg

More information

Atrial fibrillation (AF) is a disorder seen

Atrial fibrillation (AF) is a disorder seen This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,

More information

Sudden death as co-morbidity in patients following vascular intervention

Sudden death as co-morbidity in patients following vascular intervention Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,

More information

Postoperative atrial fibrillation predicts long-term survival after aortic-valve surgery but not after mitral-valve surgery: a retrospective study

Postoperative atrial fibrillation predicts long-term survival after aortic-valve surgery but not after mitral-valve surgery: a retrospective study Open Access To cite: Girerd N, Magne J, Pibarot P, et al. Postoperative atrial fibrillation predicts long-term survival after aortic-valve surgery but not after mitral-valve surgery: a retrospective study.

More information

A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents

A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1

More information

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with

More information

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Right Coronary Artery Stenosis: An Independent Predictor of Atrial Fibrillation After Coronary Artery Bypass Surgery

Right Coronary Artery Stenosis: An Independent Predictor of Atrial Fibrillation After Coronary Artery Bypass Surgery 198 JACC Vol. 25, No. l January 1995:198-202 Right Coronary Artery Stenosis: An Independent Predictor of Atrial Fibrillation After Coronary Artery Bypass Surgery LISA A. MENDES, MD, GILBERT P. CONNELLY,

More information

Results from RE-LY and RELY-ABLE

Results from RE-LY and RELY-ABLE Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent

More information

Short and Long Term Outcomes of Patients Admitted with Unexplained Syncope Using a Simple Novel SELF-Pathway

Short and Long Term Outcomes of Patients Admitted with Unexplained Syncope Using a Simple Novel SELF-Pathway Short and Long Term Outcomes of Patients Admitted with Unexplained Syncope Using a Simple Novel SELF-Pathway Eyal Herzog MD, FACC, Chaithanya K Pamidimukala, MBBS, Ammy Malinay, RN, Alexandre M Benjo,

More information

Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic

Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston

More information

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,

More information

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt

More information

Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE

Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the

More information

Complicanze aritmiche in riabilitazione dopo CCH.

Complicanze aritmiche in riabilitazione dopo CCH. Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at

More information

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias

More information

SESSION 5 2:20 3:35 pm

SESSION 5 2:20 3:35 pm SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:

More information

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance

More information

Chapter 4: Cardiovascular Disease in Patients with CKD

Chapter 4: Cardiovascular Disease in Patients with CKD Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%

More information

Catheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?

Catheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF? : Another Option for AF Atrial fibrillation (AF) is a highly common cardiac arrhythmia and a major risk factor for stroke. In this article, Dr. Khan and Dr. Skanes detail how catheter ablation significantly

More information

Course: Exercise and Aging for Special Populations

Course: Exercise and Aging for Special Populations Copyright EFS Inc. All Rights Reserved. Course: Exercise and Aging for Special Populations Session 2: Cardiovascular and Metabolic Disease Considerations for Exercise Program Design Presentation Created

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Methods. Washington, DC and Hines, Illinois

Methods. Washington, DC and Hines, Illinois 942 JACC Vol. 32, No. 4 Prevalence and Significance of Nonsustained Ventricular Tachycardia in Patients With Premature Ventricular Contractions and Heart Failure Treated With Vasodilator Therapy STEVEN

More information

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty

More information

Linköping University Post Print. Atrial fibrillation and platelet reactivity

Linköping University Post Print. Atrial fibrillation and platelet reactivity Linköping University Post Print Atrial fibrillation and platelet reactivity Micha Milovanovic, Elisabeth Fransson, Claes Hallert and Petter Järemo N.B.: When citing this work, cite the original article.

More information

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39 Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often

More information

DICOM Correction Item

DICOM Correction Item Correction Number CP-759 DICOM Correction Item Log Summary: Type of Modification Modification Rationale for Correction Name of Standard PS 3.16 The templates for Cardiovascular Patient History, originally

More information